Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Mereo BioPharma Group plcNASDAQ: MREO

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 21.6% from a year ago

Net receivables stood at $1.88M at the end of Q1 FY2026, down 21.6% from a year earlier and up 25.5% from the prior quarter.

Context

  • Net receivables amounted to 4.6% of total assets at the end of Q1 FY2026, up 1.1 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -21.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.88M+25.5% QoQ
Last fiscal yearDec 2025
$1.98M-39.0% YoY
Year agoMar 2025
$2.4M-21.6% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.6%——
1 year-39.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
1.98M USD
Year-over-year change
-39.0%

Net Receivables vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -21.6% is the 5th highest of 7, against a peer median of +11.6%.
  • Net receivables amounts to 4.6% of total assets for MREO, versus a peer median of 0.0%.
MREO Competitors
Net Receivables for MREO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMMPImmutep LimitedDec 2025A$37.52M AUD+2426831.8%-90.4%25.5%
SLNSilence Therapeutics plcMar 2026$22.22M USD+31.9%+199.6%19.3%
PRQRProQR Therapeutics N.V.Mar 2026€2.72M EUR-8.7%-55.1%2.7%
MREOMereo BioPharma Group plcMar 2026$1.88M USD-21.6%—4.6%
ACIUAC Immune S.A.Mar 2026CHF 1.51M CHF+63.5%+18.7%1.1%
CADLCandel Therapeutics, Inc.Mar 2026$0 USD——0.0%
CAPRCapricor Therapeutics, Inc.Mar 2026$0 USD-100.0%-52.4%0.0%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$0 USD——0.0%
KYTXKyverna Therapeutics, Inc.Mar 2026$0 USD——0.0%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$0 USD——0.0%
ALDXAldeyra Therapeutics, Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding MREO) —+11.6%-52.4%0.0%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents126.75M68.18M57.42M69.8M40.99M
Short-term Investments769.47K0000
Net Receivables003.73M3.25M1.98M
Inventory00000
Other Current Assets3.01M3.23M1.98M507K141K
Total Current Assets134.32M75.2M63.76M74.76M45.02M
Property, Plant & Equipment (Net)3.42M2.22M1.65M984K381K
Goodwill00000
Intangible Assets33.22M29.01M1.09M643K516K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets10000
Total Non-current Assets36.64M2.22M2.74M1.63M897K
Total Assets170.96M77.41M66.5M76.39M45.92M
Account Payables3.09M3.49M2.35M2.44M1.33M
Short-term Debt013.33M05.54M0
Tax Payables00662K770K0
Deferred Revenue00000
Other Current Liabilities7.6M1.36M2.37M(413K)1M
Total Current Liabilities16.96M24.38M9.49M13.85M4.3M
Long-term Debt19.45M04.39M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities13.17M157K1.18M1.39M699K
Total Non-current Liabilities34.99M1.64M6.48M1.57M699K
Total Liabilities51.95M26.01M15.96M15.42M5M
Common Stock2.37M2.48M2.78M3.06M3.14M
Retained Earnings(401.6M)(404.58M)(419.63M)(462.88M)(501.02M)
Accumulated OCI183.58M(21.69M)(17.49M)(18.85M)(10.82M)
Other Stockholders Equity10000
Minority Interest00000
Total Equity119.01M51.4M50.54M60.97M40.92M
Total Debt22.66M15.37M5.95M6.43M202K
Net Debt(104.08M)(52.81M)(51.47M)(63.37M)(40.79M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.